Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting

Business Wire10-18

Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476231447?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Dd4uxFwn4x2j_agA5P7AWw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2b33f4567a943891f601bf8300307940","is_english":true,"pubTime":"2024-10-18 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476231447","market":"us","top_or_hot":-1,"title":"Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting","media":"Business Wire","content":"<div>\n<p>Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cerus-corporation-announces-workshop-abstracts-123000413.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cerus-corporation-announces-workshop-abstracts-123000413.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cerus-corporation-announces-workshop-abstracts-123000413.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/cerus-corporation-announces-workshop-abstracts-123000413.html","article_id":"2476231447","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Dd4uxFwn4x2j_agA5P7AWw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2b33f4567a943891f601bf8300307940"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476231447","pubTimestamp":1729254600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical Trial. CONCORD, Calif., October 18, 2024----Cerus Corporation  today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies  Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Central Daylight Time .Monday, October 21 – 9:45 a.m. – Utilizing Sankey Diagrams to Quantify Laboratory Efficiency of INTERCEPT Fibrinogen Complex vs Traditional Cryoprecipitate . Monday, October 21, 2024 – 2:00 p.m. – Phase IV Trial of Pathogen-reduced Cry","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CDT":"Conduit Pharmaceuticals Inc.","BK4198":"医疗保健用品","CERS":"Cerus Corporation","AABB":"Asia Broadband, Inc."},"translate_title":"Cerus Corporation在2024年AABB年会上宣布研讨会和摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AABB":1,"CDT":1,"CERS":1},"content_text":"Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical Trial\nCONCORD, Calif., October 18, 2024--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.\nThe following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Central Daylight Time (CDT).\nOral Presentations\n\nSunday, October 20, 2024 – 9:30 a.m.– Acute Kidney Injury to Evaluate Amustaline/Glutathione Pathogen Reduced Red Cells in Cardiac Surgery: Outcomes of the ReCePI Phase III Clinical Trial (Speaker: E. Snyder)\nMonday, October 21 – 9:45 a.m. – Utilizing Sankey Diagrams to Quantify Laboratory Efficiency of INTERCEPT Fibrinogen Complex vs Traditional Cryoprecipitate (Speaker: D. Chen)\nMonday, October 21, 2024 – 2:00 p.m. – Phase IV Trial of Pathogen-reduced Cryoprecipitate vs. Cryoprecipitated AHF to Lower Operative Transfusions (TOPCLOT) in Cardiac Surgery (Speaker: M. Cushing)\nMonday, October 21, 2024 – 2:00 p.m. – HLA Alloimmunization in ReCePI, a Phase III Study of Amustaline/Glutathione Pathogen Reduced RBCs (Speaker: P. Norris)\nMonday, October 21, 2024 – 2:00 p.m. – Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in the ReCePI Phase III Clinical Trial (Speaker: R. Benjamin)\n\nPoster Presentations\nHeld Sunday, October 20 and Monday, October 21, 2024\n\nEvaluation of Pathogen Reduction Efficacy in Platelet Concentrates Until End of Shelf-Life with Two Different Automated Bacterial Detection Systems\nDevelopment of a Next Generation Illuminator for Photochemical Inactivation of a Broad Spectrum of Pathogens in Platelet Concentrates\nAccelerating Treatment Delivery and Reducing Waste with Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex\nWastage and Cost Analysis for INTERCEPT Fibrinogen Complex\nAn Analysis of Anesthesiologist and Transfusion Service Staff Preferences Between Pathogen Reduced Cryoprecipitated Fibrinogen Complex and Conventional Cryoprecipitated AHF\nAnalysis of Wastage, Savings, and Maternal and Pediatric Outcomes for Pooled Pathogen Reduced Cryoprecipitate versus Conventional Cryoprecipitate\nPathogen Reduced Cryoprecipitate Implementation and Assessment of Its Impact in a Large Academic Medical Center\nImplementation of INTERCEPT Fibrinogen Complex (IFC) for Postpartum Hemorrhage\nEvaluation of INTERCEPT RBC Pathogen Reduction in Combination with Irradiation\n\nIndustry Workshop\n\nMonday, October 21, 2024 – 7:00 a.m.– Industry Workshop Presented by Cerus: Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT® Blood System (Speakers: J. Squires, C. Ingold, E. Snyder)\n\nThe full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/wp-content/uploads/sites/8/2024/09/2024_AABB_AbstractBook_v6final_27Sept2024.pdf\nCerus representatives will be in the exhibition area at booth #431.\nABOUT CERUS\nCerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both C.E mark and FDA approval for these two blood components. In the U.S, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.\nINTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241018604249/en/\nContacts\nJessica HanoverCerus Corporation925-288-6137","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476231447"}